rotigotine + levodopa

Rotigotine + levodopa is a combination of two antiparkinsonian agents used together for the management of Parkinson’s disease, particularly in patients with advanced symptoms. **Rotigotine** is a non-ergot dopamine receptor agonist delivered via a transdermal patch, acting primarily by stimulating dopamine D2, D3, and D1 receptors in the brain to mimic the effects of dopamine and reduce motor symptoms such as rigidity and tremors[1][3][5]. **Levodopa** is a dopamine precursor that crosses the blood-brain barrier and is converted into dopamine, thus replacing deficient levels in patients with Parkinson’s disease. Levodopa is typically administered with carbidopa (a DOPA decarboxylase inhibitor), but in the context of "rotigotine + levodopa," this refers to the joint use of these two core dopaminergic drugs. The combination has demonstrated additive therapeutic benefits, improving motor fluctuations and reducing "off" time, but also increases the risk of dopaminergic side effects, including dyskinesia and somnolence[1][5]. This combination is not a fixed-dose single product but rather refers to the clinical practice of co-administering these agents. Rotigotine is produced as Neupro, a daily transdermal patch, while levodopa is available in various formulations (usually with carbidopa)[1][3][5].